GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Huang, He  (5)
  • Medicine  (5)
  • 1
    In: Bone Marrow Transplantation, Springer Science and Business Media LLC, Vol. 58, No. 7 ( 2023-07), p. 801-810
    Type of Medium: Online Resource
    ISSN: 0268-3369 , 1476-5365
    RVK:
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2023
    detail.hit.zdb_id: 2004030-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 156-156
    Abstract: Introduction Although steady progress of effective chemotherapy in childhood acute lymphoblastic leukemia (ALL) carried with exceeding 80% of individuals now cured, the majority of adult patients with ALL are not cured by chemotherapy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option. However, relapse remains the most leading cause of death after allo-HSCT. Adverse genetic alterations are generally accepted to be responsible for treatment failure and relapse. Several structural chromosomal alterations including rearrangement of the myeloid-lymphoid or mixed-lineage leukemia gene (MLL) and Philadelphia chromosome (Ph), have been mostly found in relapsed ALL. However, many Ph-negative (Ph-) ALL patients with normal karyotype , lacking known risk factors, also experienced relapse. The underlying pathologic determinants leading to relapse and prognostic markers in these cases remain poorly understood. More importantly, allo-HSCT is a distinct treatment option from tradtional chemotherapy and has 2 important forms to eliminate and select on malignant cells. The malignant cells that go on to causing relapse must initially survive ablation of chemotherapy before allo-HSCT and conditioning regimen in allo-HSCT. Then, after allo-HSCT, they must survive the effect of graft-versus- leukemia (GVL) reaction. Following this rationale, we hypothesized that there may be pivotal genetic causes confer leukemic cells a fitness advantage to undergo huge selective pressures and expand after allo-HSCT. To elucidate the genomic basis underlying relapse after allo-HSCT to aid to discover novel predictive biomarkers and identify therapeutic targets, we carried out the first whole-exome sequencing analysis in longitudinal matched samples from diagnosis to relapse after allo-HSCT in adult patients with the most common subtype of ALL, Ph- B-cell ALL (B-ALL). Methods Whole-exome sequencing was conducted for 9 genomic DNA samples from 3 relapsed cases with Ph- B-ALL (discovery cohort) at 3 specific time points including: diagnosis, complete remission (CR) after induction chemotherapy before allo-HSCT, relapse after allo-HSCT to discover candidate relapse-associated mutated genes. We identified putative somatic mutations by comparing each tumor ( diagnostic samples or relapsed samples) to normal (CR samples) from the same patient. To confirm candidate somatic gene mutations, screen relapse-associated gene mutations and define the frequency of somatic mutations identified by whole-exome sequencing analysis, we further carried out target genes whole coding regions sequencing in an ALL extended validation cohort including 58 adult Ph- B-ALL cases, where 27 patients experienced relapse at a median time of 6.5 (range 2-33) months after allo-HSCT and 31 patients did not relapse after allo-HSCT at a median follow-up for 34 (range 12–56) months. Results (1) We discovered novel associations of recurrently mutated genes (CREBBP, KRAS, PTPN21) with the pathogenesis of adult Ph- B-ALL relapse after allo-HSCT, which were mutated in at least two relapsed cases, but were not mutated in non- relapsed patients. (2) The generation of high-depth whole-exome sequencing data in longitudinal matched samples from diagnosis to relapse after allo-HSCT in initial 3 patients allowed us to directly assessed the evolution of somatic mutations. Our data suggested that in the progression of leukemia relapse after allo-HSCT, the relapse clone had a clear relationship to the diagnosis clone, either arising from a subclone already exsiting in the diagnostic tumor, or originating from a common preleukemic progenitor with the diagnosis clone. In the latter pattern, the relapse clone acquires new genetic alterations while retaining some but not all of the alterations found in the diagnostic tumor. In contrast, in some cases, leukemia recurrences afer allo-HSCT may be composed of second malignancies with completely distinct sets of mutations from the primary tumor. Conclusions Our study is the first to explore genetic basis of adult Ph- B-ALL from diagnosis to relapse after allo-HSCT over time, which will provide novel genetic biomarkers on risk “index” to improve individualized treatment intensification and intervention strategies, and potential therapeutic targets for Ph--ALL relapse after allo-HSCT. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Society of Hematology ; 2010
    In:  Blood Vol. 116, No. 21 ( 2010-11-19), p. 4710-4710
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 4710-4710
    Abstract: Abstract 4710 Acute promyelocytic leukemia (APL) represents 3.3%-17.4% of acute leukemia in adults. With the application of all-trans retinoic acid (ATRA), more than 85% patient can achieve complete remission, however, high rates of relapse still exist if ATRA is used alone. Primary resistance of ATRA in PML-RARα positive APL is rare during induction therapy but the incidence markedly increases after second relapse and results in poor long time survival of patient. Matrine (MAT) is the effective constituent of Radix Sophorae Flavescentis, a commonly used traditional chinese drug, and has proven ability to inhibit carcinoma cell proliferation and can induce differentiation and apoptosis of K562 cells, however its effect on the differentiation of APL cells, especially on ATRA resistant APL cells is unclear. The aim of our research is to explore the effect of MAT on alleviating retinoic acid resistance in APL cells and address possible mechanisms involved. The characteristics of ATRA sensitive APL cell strain NB4 and resistant APL cell strains NB4-R1 and NB4-R2 were described in our former studies. Dose escalation studies using MAT and ATRA was investigated using methyl thiazolyl tetrazolium (MTT) test. The toxicity of MAT increases with increasing concentration of MAT from 0.001 mmol/L to 10 mmol/L, and the 0.1mmol/L was chosen with its inhibition ratio 〈 10%. IC50 of ATRA was obtained by drawing the restrain curve; the resistance coefficient (RC) of NB4-R1 and NB4-R2 to ATRA was obtained by the ratios of their IC50 to that of NB4 cell, respectively. And the reversal index (RI) was obtained by the ratios of RC of resistant cell line cells cultured with or without 0.1 mmol/L MAT for 72h. Cell differentiation was evaluated by nitro blue tetrazolium chioride (NBT) test and cell morphology. Differential effects on cell differentiation between MAT combined with 1 umol/L ATRA and controls were observed. For these studies, 1umol/L of ATRA was chosen according to the result of IC50 test, which had low toxicity to resistance cell line cells, with the inhibition ratio 〈 10%. Apoptosis rate of cells treated with MAT combined with 1 umol/L ATRA was tested by flow cytometry with Annexin V-PI staining. Nested PCR was used for PML/RARa PCR reaction. Our results showed, after treated with ATRA along with 0.1 mmol/L MAT, the resistance factor of NB4-R1 to ATRA decreased markedly (RI=4.96±1.15), but no difference was shown in NB4-R2 cells (RI=0.66±0.17). The positive ratio of NBT and the morphologic changes indicated that the differentiation ability of NB4 and NB4-R1was enhanced significantly with the increasing concentration of MAT combined with 1 umol/L ATRA, which reached the peak at 0.1mmol/L (Figure). The apoptosis ratio (Annexin V-FITC kit) of NB4 and NB4-R1 were also increased with increasing concentration of MAT combined with 1 umol/L ATRA, while no changes were observed using the NB4-R2 cell line. The expression of PML-RARα fusion became weak in NB4 and NB4-R1 cells after treated with 0.1 umol/L ATRA alone, and decreased notably when co-treated with 0.1 mmol/L MAT for 72h in NB4-R1, while the fusion gene expression remained negative in NB4-R2 cells exposed to both drugs. From this study, we conclude that MAT, when used together with ATRA as a low non-toxic dose, can improve the differentiation of NB4 cells and inverse the retinoic acid resistance of NB4-R1 cells, but it has no function on NB4-R2 cells. As the mechanism of ATRA resistance in NB4-R1 and NB4-R2 cells is different, with resistance to the former ascribed to abnormal cyclic adenosine monophosphate (cAMP) mediated pathways, leading to altered differentiation of NB4-R1 which can be corrected when cells are cocultured with cAMP and ATRA, and resistance of NB4-R2 is owing to the variation of PML-RARα, which can only be alleviated in the existence of RXR receptor specific agonist, MAT may play its anti-ATRA resistance role in an ATRA dependent pathway, and lead to the inhibition of the PML-RARα fusion gene. This indicates a possible application of MAT in ATRA resistance therapy. Further research will focus on the mechanism of MAT in the regulation and differentiation as well as apoptosis of APL cells. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Society of Hematology ; 2010
    In:  Blood Vol. 116, No. 21 ( 2010-11-19), p. 5068-5068
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 5068-5068
    Abstract: Abstract 5068 A 33-year-old man of Asian descent was admitted to our hospital 3 years ago with a main complaint of palpitations for 7 months. There was no fever, no cough, no gain or loss of weight, no night sweats, no medical history of allergic diseases or contact with parasites. Physical examination showed marked edema in the neck and upper chest, and the hepatojugular reflux was positive. There was no change in skin appearance or hepatosplenomegaly. A soft rubbery, non-tender lymph node (1×2cm) was palpated in the left axillary area. The laboratory data showed mild eosinophilia (leukocyte count 6000 /ul with eosinophils 582/ul). The serum IgE concentration was increased (1,250 U/ml). Serological tests for HBsAg, anti-HCV, anti-HIV, and antibodies for distoma pulmonala, distoma japonicum, schistosome, bladder worm, sparganum, trichina cystica and filarial were negative, however toxoplasma gondii antibody IgG was positive, while the IgM was negative. Antinuclear antibodies were all negative. Echocardiogram revealed a mass (7.1×7.0×5.5cm) displacing the base of the heart and involving both atria. CT showed enlarged biaxillary lymph nodes and a large mediastinal mass extending into both atria and obstructing the superior vena cava with right ventricular hypertrophy (Fig.1a, b). Positron emission tomography (18F-FDG-PET) scan indicated negative fluorodeoxyglucose (FDG) uptake in the lymph nodes, spleen and liver. Biopsy of an enlarged right axillary lymph node was performed and the pathology revealed a normal preserved nodal architecture with proliferation of lymphoid follicles infiltrated by abundant eosinophils partially forming eosinophilic microabscesses. CD20 staining was positive. The bone marrow examination indicated normal cellularity except a little increase of eosinophils at 7.5%. Biopsy of the cardiac mass was not performed due to technical challenges related to its anatomical location. Based on the clinical and laboratory findings, a diagnosis of Kimura disease was established. Treatment was started with a low dose of oral prednisone 20–30mg/d. After treatment, the enlarged lymph nodes diminished gradually. However, 4 months later, echocardiogram showed the mediastinal mass remained, with two new masses (left 5.4×3.2cm, right 4.3×2.6cm) attached to the atrial septum respectively (Fig2). Prednisone was gradually increased to 50mg/d. 3 months later, the patient was admitted to hospital with chest pain and shortness of breath. Thoracic CT showed severe obstruction of the right middle lobe bronchus by the enlarged mediastinal mass. A bone marrow smear and flow cytometric analysis did not show any clonal hematopoietic abnormality. The echocardiogram remained unchanged. Prednisone (40mg/d) was re-administered but the patient's situation was getting worse quickly. He developed dyspnea and hypoxemia, apparent SVCS, edema of the inferior extremities and recurrent arrhythmia. CHOP chemotherapy was initiated (CTX 1.0 dl, VDS 4mg dl, EPI-ADM 60mg dl, DXM 10mg dl-2) but he died due to cardiac and respiratory failure. Kimura's Disease is a distinct clinicopathological entity accompanied by peripheral blood eosinophilia and elevated serum IgE level. Though rare, KD with cardiovascular involvement has been reported in several cases. This kind of involvement is also named as Eosinophilic Myocarditis (EM), occurs in up to 60% of patients diagnosed with hypereosinophilic syndrome (HES). However, this patient only has partial response of prednisone, and relapsed after 9 months therapy with prednisone 20–50 mg/d. Although chemotherapy was added, it was too late to control the progression of disease. This instructive case demonstrates that although Kimura's disease is a benign process, infiltration of eosinophils in multiple organs may result in critical illness and can be fatal. Early intervention and frequent close followup appears essential for controlling disease in KD patients with cardiac or other critical complications. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 1938-1938
    Abstract: Abstract 1938 Background: Toll-like receptors (TLRs) are transmembrane proteins on the surface of immune cells that detect conserved molecular motifs known as “microbe-associated molecular patterns” from a variety of organisms. They interact with several adapter proteins to activate transcription factors, leading to the production of inflammatory cytokines and the activation of adaptive immunity. Current evidence suggests that common polymorphisms in TLR genes have been associated with the susceptibility to autoimmune disease and several infections, their association with outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has yet to be explored. Methods: We unselectively included all patients undergoing allo-HSCT in our Bone Marrow Transplantation Center between January 2001 and March 2009 if donor and patient DNA were available. All the patients and their donors were from a homogeneous genetic background. We analyzed 10 single nucleotide polymorphisms (SNPs) in the TLR1gene (rs4833095 C/T, rs5743565 A/G), TLR2gene (rs11938228 A/C, rs3804099 C/T), TLR3 gene (rs3775291 A/G, rs3775296 G/T), TLR8gene (rs3764880 A/G, rs2159377 C/T) and TLR9 gene (rs352139 G/A, rs352140 C/T) in 2 independent cohorts. The initial cohort consisted of 138 pairs of patients and their unrelated donors (URDs). The second cohort consisted of 102 pairs of patients and their HLA-identical sibling donors. Results: (1) We found that two SNPs in donor side, TLR9 +1174 G/A (rs352139) and TLR9 +1635 C/T (rs352140), influenced the risk of aGVHD. The association was particularly strong in the URD transplantation cohort. Multivariate analysis confirmed that an unrelated donor with the TLR9 +1174 variant allele (A allele) was an independent risk factor for aGVHD (P= 0.009, RR= 3.123). In contrast, an unrelated donor with the TLR9 +1635 variant genotype (TT) was protective (P= 0.067, RR= 3.457). The same effect was observed in the sibling transplantation cohort, although the incidence of clinically significant aGVHD in this cohort was low overall and the association was not statistically significant. (2) Since cytomegalovirus (CMV) reactivation and disease continued to be important complications post-HSCT, and CMV infection is of special concern in the Chinese population. The incidence of asymptomatic infection is high. The episodes of major infection were focused on early CMV infection post-HSCT. Early CMV infection refers to antigenemia or disease with onset by day 100 after transplantation. In the present study cohorts, all patients and almost all donors were CMV seropositive (CMV-specific immune globulin G positive, CMV-IgG(+)) before HSCT and only one donor from the Taiwan Tzu Chi Stem Cells Center was CMV seronegative. All patients received CMV prophylaxis treatment and those experiencing pre-transplantation CMV recurrent infection received preemptive treatment. Of the total of 240 patients, 134 (55.8%) had experienced early CMV infection with a median onset of 27 days (range 2–64) post-HSCT. Patients who received stem cells from donors with the TLR9 +1635 variant genotype (TT) had a reduced incidence of grades II–IV aGVHD, however, they experienced early CMV infection more frequently than those with the wild-type genotype (CT or TT) in both the URD transplantation cohort (TT: 80% vs. CT or CC: 59.3%, Gray's test p =0.02) and the sibling transplantation cohort (TT: 66.7% vs. CT or CC: 41.7%, Gray's test p=0.03), although a higher incidence of early CMV infection was observed in the URD transplantation cohort (63% vs. 46%, Gray's test p = 0.025). Multivariate analysis confirmed unrelated donors (p =0.046, RR = 1.438, 95%CI,1.007–2.053), patients experiencing recurrent CMV infection pre-transplantation (p = 0.004, RR = 0.597, 95%CI, 0.419–0.849) and donors with the TLR9 +1635 TT genotype (p=0.005, RR=0.561, 95%CI, 0.376–0.836) all contributed to the development of early CMV infection. Conclusion: There is increasing evidence for a role for TLR9 in the pathogenesis of aGVHD and viral infection. These result is the first report of donor TLR9 gene polymorphic features with the risk of aGVHD and early CMV infection, which are located within the promoter region and coding polymorphisms and may influence transcriptional regulation and the amino acid exchange of the TLR9 gene. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...